by Truveta staff | Mar 12, 2026 | Research
Authors: Cheng Cao ⊕Truveta, Inc, Bellevue, WA, Jay Pillai ⊕Truveta, Inc, Bellevue, WA, Sara Daraei ⊕Truveta, Inc, Bellevue, WA, Sina Ghadermarzi ⊕Truveta, Inc, Bellevue, WA Key points Peer-reviewed paper, “Linking patient records at scale with a hybrid approach...
by Truveta staff | Mar 4, 2026 | Research
Substance use disorder (SUD) affects nearly 16.8% of Americans aged 12 and older, or more than 48 million people in the US. It is commonly seen in clinical practice, but rarely simple. In healthcare records, SUD does not always present as a single, stable diagnosis....
by Truveta staff | Feb 25, 2026 | Research
Older adults remain at highest risk for COVID-19–related hospitalization. Yet a new CDC analysis suggests that effective antiviral treatments are likely underprescribed among outpatients aged 65 or older, with prescribing patterns varying alongside disease...
by Truveta staff | Feb 18, 2026 | Research
In this Truveta experts analysis, Amy Sullivan, MS examines real-world antidepressant prescribing episodes using linked electronic health record (EHR) and closed claims data from more than 14.5 million individuals. The analysis characterizes the duration, recurrence,...
by Truveta staff | Feb 12, 2026 | Research
Two new peer-reviewed studies published in the Journal of Cardiac Failure showcase how clinicians and researchers at Baylor Scott & White Research Institute, working in collaboration with Baylor Scott & White Health and Stony Brook Medicine investigators, are...
by Truveta Research | Feb 11, 2026 | Research
A large proportion of early users (36.1%) of oral semaglutide (Wegovy pill) had no prior evidence of GLP-1-based medication use, suggesting rapid uptake among patients new to taking GLP-1 medications. Among patients who previously used a GLP-1-based medication, most...
